药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Potassium cation
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Cannabidiol.
Potassium cation
Bezitramide
The risk or severity of serotonin syndrome can be increased when Bezitramide is combined with Cannabidiol.
Potassium cation
Mephentermine
The risk or severity of serotonin syndrome can be increased when Mephentermine is combined with Cannabidiol.
Potassium cation
Remimazolam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Remimazolam.
Potassium cation
Lemborexant
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Lemborexant.
Potassium cation
Cannabinol
The risk or severity of adverse effects can be increased when Cannabinol is combined with Cannabidiol.
Potassium cation
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Cannabidiol.
Potassium cation
Nabiximols
The risk or severity of adverse effects can be increased when Nabiximols is combined with Cannabidiol.
Potassium cation
WIN 55212-2
The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Cannabidiol.
Potassium cation
Surinabant
The risk or severity of adverse effects can be increased when Surinabant is combined with Cannabidiol.
Potassium cation
Ibipinabant
The risk or severity of adverse effects can be increased when Ibipinabant is combined with Cannabidiol.
Potassium cation
Ajulemic acid
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Cannabidiol.
Potassium cation
GW842166
The risk or severity of adverse effects can be increased when GW842166 is combined with Cannabidiol.
Potassium cation
Carfentanil, C-11
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Carfentanil, C-11.
Potassium cation
JNJ-26489112
The risk or severity of adverse effects can be increased when Cannabidiol is combined with JNJ-26489112.
Potassium cation
Bentazepam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Bentazepam.
Potassium cation
Pyrazolam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Pyrazolam.
Potassium cation
Cinazepam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Cinazepam.
Potassium cation
Oxazepam acetate
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Oxazepam acetate.
Potassium cation
Perphenazine enanthate
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Perphenazine enanthate.